ライフサイエンスコーパス: treatment adherence

1 ty in case of suboptimal treatment (e.g. low treatment adherence).

2 ddress issues of safety and problems of poor treatment adherence.

3 nd potential adverse effects, leading to low treatment adherence.

4 Both groups exhibited moderate treatment adherence.

5 promote informed decision-making and improve treatment adherence.

6 also highlighted the critical importance of treatment adherence.

7 rates of healthcare seeking, diagnosis, and treatment adherence.

8 sion modeled characteristics associated with treatment adherence.

9 ation for regular dental visits and improved treatment adherence.

10 avoiding the adverse side effects that limit treatment adherence.

11 romote patient engagement, satisfaction, and treatment adherence.

12 GTCAT were also correlated with the rates of treatment adherence.

13 ed all patients as randomized, regardless of treatment adherence.

14 , and other patient determinants on ADRs and treatment adherence.

15 events, dropouts due to adverse effects, and treatment adherence.

16 s, family, and friends was a facilitator for treatment adherence.

17 lifestyles, optimise medication, and improve treatment adherence.

18 re were no differences in service contact or treatment adherence.

19 ia that compromise quality of life and limit treatment adherence.

20 er treatment initiation among women or lower treatment adherence.

21 ex disparity in treatment initiation and not treatment adherence.

22 creasing rates of treatment, monitoring, and treatment adherence.

23 onal incentives contingent on abstinence and treatment adherence.

24 ing, willingness to adhere to treatment, and treatment adherence.

25 essing the ingestion of oral medications and treatment adherence.

26 easures that may prevent relapse and improve treatment adherence.

27 vels of psychosocial well-being and rates of treatment adherence.

28 only one tablet once-a-day, which increases treatment adherence.

29 Three studies added to the understanding of treatment adherence.

30 hanced by community-based social support for treatment adherence.

31 be an important consideration in maximizing treatment adherence.

32 , 0.88-3.89-borderline), partial/poor asthma treatment adherence (2.54, 0.97-6.67-borderline), and an

33 sed phototherapy, was associated with better treatment adherence (202 patients [51.4%] vs 62 patients

34 Because of inadequate clinical follow-up or treatment adherence, 2251 infants were included in the p

35 t inclusion, 20.9% of patients reported good treatment adherence, 72.0% minor nonadherence, and 7.1%

36 -term outcomes, clarify the association with treatment adherence, a key predictor of outcome in TBM,

37 Treatment adherence, adverse effects, and effectiveness

38 treatment has affected viral suppression or treatment adherence among individuals who self-reported

39 We examine differences by education in treatment adherence among patients with two illnesses, d

40 h, can negatively affect quality of life and treatment adherence among people with human immunodefici

41 re continuum (engagement in care, medication/treatment adherence) among women with HIV in Rwanda.

42 Treatment adherence analysis supported a dose-response e

43 adication therapy failure, particularly when treatment adherence and antibiotic susceptibility are co

44 s and HSRs represent significant barriers to treatment adherence and are recognised risk factors for

45 This study investigated treatment adherence and associated factors among people

46 epression in primary care resulted in better treatment adherence and better clinical outcomes at 4 an

47 therapy sessions holds promise for improving treatment adherence and completion among depressed patie

48 Patients were compared on treatment adherence and completion and on 1-year rehospi

49 ivational therapy intervention on outpatient treatment adherence and completion for patients with com

50 We will also discuss how treatment adherence and dedicated transition care can af

51 als, which had found greater improvements in treatment adherence and depressive symptoms at 4 and 7 m

52 Patient benefits, such as increased treatment adherence and enhanced adaptation, need to be

53 44-fold significantly higher likelihood when treatment adherence and H pylori clarithromycin suscepti

54 lower literacy is recommended to strengthen treatment adherence and improve clinical outcomes.

55 procedures may have a substantial impact on treatment adherence and improve long-term health outcome

56 Addressing barriers to treatment adherence and improving early detection and pr

57 ntions for reducing incidence were improving treatment adherence and increasing testing frequency and

58 at 6 months and every 12 months, to monitor treatment adherence and minimize failure, and will publi

59 hnic groups and how they are associated with treatment adherence and mortality disparities.

60 ons were effective at improving tuberculosis treatment adherence and outcomes, and the trial suggests

61 CFs' characteristics usually associated with treatment adherence and outcomes, were also considered i

62 ients with adherence issues, on tuberculosis treatment adherence and outcomes.

63 e target for intervention aimed at improving treatment adherence and outcomes.

64 cts that have major consequences in terms of treatment adherence and patients' quality of life.

65 e the association between race/ethnicity and treatment adherence and persistence among patients with

66 e found to display racial differences in the treatment adherence and persistence of biologics, with s

67 However, the rates of treatment adherence and premature discontinuation of tre

68 ying anorexia and weight loss that may limit treatment adherence and reduce patient quality of life.

69 To combat stigma, and improve HIV treatment adherence and retention among MSMW, culturally

70 combinations (FDC) has been shown to improve treatment adherence and risk factor control.

71 t centricity and patient education to ensure treatment adherence and satisfaction with care provision

72 alth information of high quality may promote treatment adherence and self-management for patients wit

73 ve diagnoses, together with an evaluation of treatment adherence and side-effects from medications.

74 bstantial indirect costs that interfere with treatment adherence and stress patients and their relati

75 mental disorders, technologies for promoting treatment adherence and supporting recovery, online self

76 It has been suggested that SDM can improve treatment adherence and that ignoring patients' personal

77 cation fatigue that might lead to suboptimal treatment adherence and the emergence of drug-resistant

78 Given the potential of depression to reduce treatment adherence and thus increase the risk of glauco

79 itching among biologics was allowed for both treatment adherence and treatment persistence.

80 l factors), pathophysiology, and response to treatments (adherence and relapse) of drug dependence vs

81 ms, regular patient follow-up, monitoring of treatment adherence, and a prominent role for the mental

82 sensitivity analyses following per-protocol, treatment adherence, and complete case analysis approach

83 alth issue, with poor clinical outcomes, low treatment adherence, and early dropouts being major chal

84 ted with fewer hospital readmissions, higher treatment adherence, and higher patient satisfaction and

85 including impaired quality of life, reduced treatment adherence, and increased disease-related morbi

86 es are recommended to evaluate risk factors, treatment adherence, and long-term outcomes.

87 luding patient self-administration, improved treatment adherence, and reduced healthcare costs.

88 decreased cognition leading to problems with treatment adherence, and the role of screening and basic

89 ioural factors including self-management and treatment adherence, and therefore, there is a reasonabl

90 it undermines HIV testing, linkage to care, treatment adherence, and viral load suppression.

91 ch patterns of direct-acting antiviral (DAA) treatment adherence are associated with SVR in this popu

92 reover, access to care, linkage to care, and treatment adherence are challenging for such a marginali

93 energy, the rewards associated with optimal treatment adherence are worth the effort.

94 ly decreases the likelihood of remission and treatment adherence but also increases the risk of disab

95 py require support to insure a high level of treatment adherence, but the evidence about effective in

96 logical therapeutics and will likely improve treatment adherence by providing long-acting effects ove

97 Treatment adherence can be measured by use of a variety

98 ence (Cohen d = 0.58; 95% CI, 0.47-0.69) and treatment adherence (Cohen d = 0.62; 95% CI, 0.40-0.84)

99 Patients receiving TTFC maintained better treatment adherence compared with patients receiving TRA

100 blished factors like exogenous exposures and treatment adherence contribute to variability in asthma

101 In the binocular group, treatment adherence data from the iPad device indicated

102 point abstinence at 9 weeks and 6 months, TB treatment adherence (days receiving TB treatment), TB tr

103 Instruments that assessed attachment, treatment adherence, depression, diabetes severity, pati

104 aviours related to opioid use help to ensure treatment adherence, detect NMOU and support therapeutic

105 examining the effect of patient dropout and treatment adherence did not alter the results.

106 avioural, and social functioning, as well as treatment adherence, disease progression, and wider fami

107 portional hazards models adjusted for recent treatment adherence estimated the relative risk of virol

108 g; management recommendations for incomplete treatment adherence; expanded eligibility for simplified

109 , treatment completion, case management, and treatment adherence for tuberculosis.

110 oring behavior following a recently proposed treatment adherence framework.

111 of pediatric CML (suboptimal response, poor treatment adherence, growth retardation, and presentatio

112 er quality that is a source of risk and high treatment adherence (>90% of water consumed is treated).

113 f virologic failure in the setting of recent treatment adherence (hazard ratio, 3.45 [95% confidence

114 Treatment adherence in 32 (30.2%) patients was <=80%.

115 improve glaucoma self-management may improve treatment adherence in a vulnerable population.

116 e development of substance use disorders and treatment adherence in bipolar youth are necessary to im

117 ng device informed interventions may improve treatment adherence in children and adolescents with chr

118 ider communication is associated with poorer treatment adherence in patients with diabetes.

119 However, little is known about treatment adherence in teenage and young adult (TYA) pat

120 d dosing schedule of B(200)PaZ could improve treatment adherence in the field.

121 imen estimand assessed effects regardless of treatment adherence in the intention-to-treat population

122 Factors that have been shown to affect treatment adherence in TYA patients include patient emot

123 he lack of interventional studies addressing treatment adherence in TYA patients with cancer, with on

124 enhance psychosocial well-being and increase treatment adherence in young adult patients with advance

125 ogist alliance, psychosocial well-being, and treatment adherence in young adults with advanced cancer

126 ation self-administration (MSA) lead to poor treatment adherence, increased hospitalizations and high

127 ions as assigned at initiation regardless of treatment adherence ("initiator") and received according

128 effectiveness and cost-effectiveness of HIV treatment adherence intervention strategies.

129 promising human immunodeficiency virus (HIV) treatment adherence interventions have been identified,

130 We conclude that treatment adherence is a key factor for a positive outco

131 duced MACCE recurrence risk, suggesting that treatment adherence is a key factor in secondary cardiov

132 urthermore, understanding predictors of poor treatment adherence is a necessary step toward developin

133 However, treatment adherence is essential to achieve the therapeu

134 gain, leading to further morbidity and poor treatment adherence, is a common consequence of treatmen

135 e in important clinical outcomes, such as HF treatment adherence, is unclear.

136 ement, patient eligibility, patient consent, treatment adherence, loss to follow-up, and missing foll

137 were associated with improved HT control and treatment adherence, mainly evaluated in US settings.

138 ons, combined with the reality of suboptimal treatment adherence, make drug resistance a clinical and

139 ion of causes, such as food insecurity, poor treatment adherence, malabsorption, uncontrolled diabete

140 Treatment adherence (medication possession ratio [MPR])

141 nclature, prevalence, origins, and effect on treatment adherence of TCS phobia in atopic dermatitis.

142 models were used to assess the influence of treatment adherence on LF infection indicators.

143 Treatment adherence, optimization of the administration

144 nse to binocular treatment was owing to poor treatment adherence or lack of treatment effect.

145 as a threshold to initiate investigations of treatment adherence or possible treatment failure.

146 ies assessing abstinence and the 2 assessing treatment adherence outcomes.

147 tions to physicians and helped patients with treatment adherence over 24 months.

148 WC2031 could improve treatment adherence over twice-daily Vibramycin.

149 the associations between SVR and 6 types of treatment adherence patterns.

150 to evaluate the relationship between DFS and treatment adherence (persistence [duration] and complian

151 s with UC, no significant differences in the treatment adherence/persistence were observed between di

152 e the association between race/ethnicity and treatment adherence/persistence.

153 eened for coexisting psychosocial issues and treatment adherence problems.

154 ons to identify areas of priorities and plan treatment adherence programs using surveillance data.

155 tions to identify areas of priority and plan treatment-adherence programs using surveillance data.

156 on should be a priority if one is to improve treatment adherence, quality of life, and outcomes in tr

157 The treatment adherence rate was 91.04%.

158 mes included stereoacuity, binocular VA, and treatment adherence rates, analyzed by a 1-sample Wilcox

159 itive to the cost of protease inhibitors and treatment adherence rates.

160 After adjustment for treatment adherence, recurrent VTE was reduced by 42% (H

161 lower levels of psychosocial well-being and treatment adherence relative to patients with cancer in

162 eful in characterizing study populations, in treatment adherence research, and as a clinical and rese

163 Persistence was lower with treatment adherence (risk ratio, 0.4 [0.2 to 0.9]).

164 Secondary outcomes included treatment adherence, safety and SVR12 in patients who we

165 ce at bimonthly and random call-back visits, treatment adherence, satisfaction, and changes in HIV, H

166 a treatment response of 50%, although better treatment adherence showed a higher response.

167 uberculosis drugs; and strategies to improve treatment adherence, such as directly observed therapy,

168 safer, highly effective MDR-TB regimens; and treatment adherence support are critically needed to opt

169 We assessed the effect of automated treatment adherence support delivered via mobile phone s

170 lly meaningful outcome indicators, including treatment adherence, symptom remission, and quality of l

171 while also considering the mediating role of treatment adherence (TA).

172 ied the prognostic impact of age, as well as treatment adherence/toxicity patterns according to age,

173 testing, linkage to care, treatment uptake, treatment adherence, treatment completion, treatment out

174 ohort study from Brazil to evaluate glaucoma treatment adherence using a medication event monitoring

175 y eczema risk; and analysis of the effect of treatment adherence using pooled complier-adjusted-causa

176 d endline surveys and clinical data assessed treatment adherence, viral suppression, retention in car

177 Treatment adherence was 100%.

178 vs usual care groups, respectively, mean TB treatment adherence was 174.3 (SD, 21.5) days vs 178.0 (

179 % male), 89.9% completed the trial; the mean treatment adherence was 98.5%.

180 Higher treatment adherence was associated with greater reductio

181 Treatment adherence was better with 4 months of rifampin

182 Treatment adherence was excellent in both groups (cinnam

183 Treatment adherence was favorable and similar between tr

184 Treatment adherence was good and few patients discontinu

185 Treatment adherence was measured as the proportion of da

186 Treatment adherence was monitored.

187 Despite the reported difficulties, treatment adherence was observed to be high.

188 Treatment adherence was similar in African American and

189 The inverse probability of the treatment adherence weighting method was used to estimat

190 tly favored study patients, but IL28B GT and treatment adherence were the most important factors dete

191 th them, and might help to improve long-term treatment adherence when symptoms cannot be alleviated e

192 We also correlated rates of treatment adherence with clinical, demographical variabl

193 study in Latin America to evaluate glaucoma treatment adherence with MEMS devices and correlate adhe

194 timely initiation of ART, and high levels of treatment adherence with viral load suppression.

195 of symptoms, difficulties with eating food, treatment adherence, worry about symptoms and illness, f